Drug intelligence / Profile preview

mAb5

Development stage: Preclinical
Lead developer: Stainwei Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

mAb5 is a monoclonal antibody currently in preclinical development by Stainwei Biotechnology (Suzhou Stainwei Biotech Inc.). It is designed to target SG27 for the treatment of various oncology indications (tumors). As a pipeline candidate, specific details regarding its epitope binding or the exact biological role of the SG27 target in tumor progression have not been publicly disclosed. The drug represents part of Stainwei's broader portfolio of therapeutic antibodies targeting cancer and inflammatory diseases.

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)

Beyond the preview

Go deeper on mAb5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mAb5.

Explore the full profile